Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa
Background:
The World Health Organization estimates that in sub-Saharan Africa about 4 million HIV-infected patients had started antiretroviral therapy (ART) by the end of 2008. Loss of patients to follow-up and care is an important problem for treatment programmes in this region. As mortality is high in these patients compared to patients remaining in care, ART programmes with high rates of loss to follow-up may substantially underestimate mortality of all patients starting ART.
Methods and Findings:
We developed a nomogram to correct mortality estimates for loss to follow-up, based on the fact that mortality of all patients starting ART in a treatment programme is a weighted average of mortality among patients lost to follow-up and patients remaining in care. The nomogram gives a correction factor based on the percentage of patients lost to follow-up at a given point in time, and the estimated ratio of mortality between patients lost and not lost to follow-up. The mortality observed among patients retained in care is then multiplied by the correction factor to obtain an estimate of programme-level mortality that takes all deaths into account. A web calculator directly calculates the corrected, programme-level mortality with 95% confidence intervals (CIs). We applied the method to 11 ART programmes in sub-Saharan Africa. Patients retained in care had a mortality at 1 year of 1.4% to 12.0%; loss to follow-up ranged from 2.8% to 28.7%; and the correction factor from 1.2 to 8.0. The absolute difference between uncorrected and corrected mortality at 1 year ranged from 1.6% to 9.8%, and was above 5% in four programmes. The largest difference in mortality was in a programme with 28.7% of patients lost to follow-up at 1 year.
Conclusions:
The amount of bias in mortality estimates can be large in ART programmes with substantial loss to follow-up. Programmes should routinely report mortality among patients retained in care and the proportion of patients lost. A simple nomogram can then be used to estimate mortality among all patients who started ART, for a range of plausible mortality rates among patients lost to follow-up.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000390
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000390
Souhrn
Background:
The World Health Organization estimates that in sub-Saharan Africa about 4 million HIV-infected patients had started antiretroviral therapy (ART) by the end of 2008. Loss of patients to follow-up and care is an important problem for treatment programmes in this region. As mortality is high in these patients compared to patients remaining in care, ART programmes with high rates of loss to follow-up may substantially underestimate mortality of all patients starting ART.
Methods and Findings:
We developed a nomogram to correct mortality estimates for loss to follow-up, based on the fact that mortality of all patients starting ART in a treatment programme is a weighted average of mortality among patients lost to follow-up and patients remaining in care. The nomogram gives a correction factor based on the percentage of patients lost to follow-up at a given point in time, and the estimated ratio of mortality between patients lost and not lost to follow-up. The mortality observed among patients retained in care is then multiplied by the correction factor to obtain an estimate of programme-level mortality that takes all deaths into account. A web calculator directly calculates the corrected, programme-level mortality with 95% confidence intervals (CIs). We applied the method to 11 ART programmes in sub-Saharan Africa. Patients retained in care had a mortality at 1 year of 1.4% to 12.0%; loss to follow-up ranged from 2.8% to 28.7%; and the correction factor from 1.2 to 8.0. The absolute difference between uncorrected and corrected mortality at 1 year ranged from 1.6% to 9.8%, and was above 5% in four programmes. The largest difference in mortality was in a programme with 28.7% of patients lost to follow-up at 1 year.
Conclusions:
The amount of bias in mortality estimates can be large in ART programmes with substantial loss to follow-up. Programmes should routinely report mortality among patients retained in care and the proportion of patients lost. A simple nomogram can then be used to estimate mortality among all patients who started ART, for a range of plausible mortality rates among patients lost to follow-up.
: Please see later in the article for the Editors' Summary
Zdroje
1. World Health Organization 2009 Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. 2009 Progress Report. WHO, Geneva. Available: http://www.who.int/hiv/pub/2009progressreport/en/index.html. Accessed 6 December 2010
2. GilksCF
CrowleyS
EkpiniR
GoveS
PerriensJ
2006 The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 505 510
3. IversLC
KendrickD
DoucetteK
2005 Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41 217 224
4. KeiserO
OrrellC
EggerM
WoodR
BrinkhofMW
2008 Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 5 e148 doi:10.1371/journal.pmed.0050148
5. MillsEJ
NachegaJB
BuchanI
OrbinskiJ
AttaranA
2006 Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 296 679 690
6. RosenS
FoxMP
GillCJ
2007 Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4 e298 doi:10.1371/journal.pmed.0040298
7. BrinkhofMW
DabisF
MyerL
BangsbergDR
BoulleA
2008 Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86 559 567
8. BrinkhofMW
Pujades-RodriguezM
EggerM
2009 Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4 e5790 doi:10.1371/journal.pone.0005790
9. MayM
BoulleA
PhiriS
MessouE
MyerL
2010 Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376 449 457
10. GrimesDA
2008 The nomogram epidemic: resurgence of a medical relic. Ann Intern Med 149 273 275
11. PortaM
2008 A Dictionary of Epidemiology. Fifth Edition. Oxford University Press 167
12. AnglaretX
ToureS
GourvellecG
TchehyA
ZioL
2004 Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa. J Acquir Immune Defic Syndr 35 320 323
13. YuJK
ChenSC
WangKY
ChangCS
MakombeSD
2007 True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bull World Health Organ 85 550 554
14. DalalRP
MacPhailC
MqhayiM
WingJ
FeldmanC
2008 Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 47 101 107
15. FoxMP
BrennanA
MaskewM
MacPhailP
SanneI
2010 Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 15 405 413
16. DabisF
BalestreE
BraitsteinP
MiottiP
BrinkhofWGM
2005 Antiretroviral Therapy in Lower Income Countries (ART-LINC): International collaboration of treatment cohorts. Int J Epidemiol 34 979 986
17. KeiserO
AnastosK
SchechterM
BalestreE
MyerL
2008 Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13 870 879
18. ForsterM
BaileyC
BrinkhofMW
GraberC
BoulleA
2008 Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86 939 947
19. McGowanCC
CahnP
GotuzzoE
PadgettD
PapeJW
2007 Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36 969 976
20. GangeSJ
KitahataMM
SaagMS
BangsbergDR
BoschRJ
2007 Cohort profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 36 294 301
21. InuiTS
NyandikoWM
KimaiyoSN
FrankelRM
MuriukiT
2007 AMPATH: Living proof that no one has to die from HIV. J Gen Intern Med 22 1745 1750
22. EinterzRM
KimaiyoS
MengechHN
Khwa-OtsyulaBO
EsamaiF
2007 Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med 82 812 818
23. YiannoutsosCT
AnMW
FrangakisCE
MusickBS
BraitsteinP
2008 Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One 3 e3843 doi:10.1371/journal.pone.0003843
24. FrangakisCE
RubinDB
2001 Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring. Biometrics 57 333 342
25. GengEH
BangsbergDR
MusinguziN
EmenyonuN
BwanaMB
2010 Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53 405 411
26. StringerJS
ZuluI
LevyJ
StringerEM
MwangoA
2006 Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 782 793
27. BraitsteinP
BrinkhofMW
DabisF
SchechterM
BoulleA
2006 Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 367 817 824
28. FerradiniL
JeanninA
PinogesL
IzopetJ
OdhiamboD
2006 Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 367 1335 1342
29. BoulleA
BockP
OslerM
CohenK
ChanningL
2008 Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 86 678 687
30. GengEH
EmenyonuN
BwanaMB
GliddenDV
MartinJN
2008 Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 300 506 507
31. LosinaE
ToureH
UhlerLM
AnglaretX
PaltielAD
2009 Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: A Cote d'Ivoire appraisal. PLoS Med 6 e1000173 doi:10.1371/journal.pmed.1000173
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 1
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication
- The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
- Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies